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Abstract: Since the discovery of RNA interference (RNAi), excitement has grown over its 
potential therapeutic uses. Targeting RNAi pathways provides a powerful tool to change 
biological processes post-transcriptionally in various health conditions such as cancer or 
autoimmune diseases. Optimum design of shRNA, siRNA, and miRNA enhances stability 
and specificity of RNAi-based approaches whereas it has to reduce or prevent undesirable 
immune responses or off-target effects. Recent advances in understanding pathogenesis of 
autoimmune diseases have allowed application of these tools in vitro as well as in vivo with 
some degree of success. Further research on the design and delivery of effectors of RNAi 
pathway and underlying molecular basis of RNAi would warrant practical use of RNAi-based 
therapeutics in human applications. This review will focus on the approaches used for 
current therapeutics and their applications in autoimmune diseases, including rheumatoid 
arthritis and Sjögren’s syndrome. 
Keywords: RNA interference; therapeutics; microRNA; small interfering RNA; 
autoimmune disease 
 
1. Introduction 
RNA interference (RNAi) is a cellular mechanism occurring in most eukaryotic cells that is 
responsible for post-transcriptional gene regulation. This process involves small single stranded RNA 
molecules binding to the 3' UTR of specific mRNA targets resulting in the degradation or translational 
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repression of that target. Since the discovery of the RNAi pathway, there has been a focused interest on 
the development of RNAi-based therapeutics for otherwise “undruggable” targets. This review will 
outline the mechanism of RNAi and approaches to RNAi-based therapeutic strategies and address the 
progress of RNAi-therapeutics for autoimmune diseases. 
The Effectors of RNA Interference 
The effectors of the RNAi pathway are small RNA (RNA) molecules that can be classified into at 
least three categories based on their origin and function: microRNAs (miRNA), short interfering RNAs 
(siRNA), and short hairpin RNAs (shRNA). 
MiRNAs represent endogenously encoded small RNAs, about 22 nucleotides long, which function 
to post-transcriptionally repress gene expression by binding to target mRNAs in a sequence specific 
manner. Though discovered relatively recently, miRNA are now recognized as key regulators of gene 
expression in plants and animals. The genes encoding miRNAs are transcribed by RNA polymerase II 
in a long primary miRNA that is cleaved in the nucleus by Drosha/DGCR8 into a precursor miRNA 
(pre-miRNA). The pre-miRNA consists of about 70 base pairs with a single-stranded hairpin loop.  
Pre-miRNA is exported from the nucleus via exportin-5, and is cleaved by Dicer in the cytoplasm to 
generate a mature miRNA about 22 nucleotides long. This mature miRNA is incorporated into a 
complex known as the RNA-induced silencing complex (RISC) where it binds to its target mRNA 
though complementary base pairing. If complementarity is perfect, mRNA degradation typically 
occurs, whereas if complementarity is partial, translational repression typically occurs [1]. 
The shRNAs are dsRNAs engineered with a similar structure as miRNA, and are either tranfected 
into cells directly or a vector encoding the shRNA is introduced into the cells and transcribed. 
SiRNA molecules are synthetic dsRNAs ranging in size from about 19–30 nucleotides that function 
to cause mRNA degradation through the perfect pairing of complementary sequences [2]. These 
molecules have become invaluable research tools to study the functions of genes and an alternative to 
knock-out mice. 
2. Approaches to RNAi Therapeutics 
2.1. Short Hairpin RNAs 
One advantage of using shRNAs is that they assimilate into the endogenous RNAi pathway, and are 
therefore more efficient than exogenously introduced siRNAs [3]. Using a viral vector-based delivery 
system for shRNAs increases transfection efficiency and allows harder-to-transfect cells such as  
non-dividing neuronal cells to be targeted. However, there are obvious safety concerns associated with 
the use of viral expression vectors in humans. Other delivery strategies for shRNA include coupling 
with monoclonal antibodies, peptides, or aptamers that recognize specific cell surface molecules, but 
each of these strategies are associated with increased toxicity [4–7]. 
2.2. MicroRNAs 
In recent years, differential expression of miRNA has been associated with a wide variety of human 
diseases ranging from many types of cancer to autoimmune diseases and everything in between. This 
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revelation makes them an attractive target for therapies. The premise is that if we can elucidate reliable 
techniques to alter miRNA levels in specific cells/tissues, perhaps we can ameliorate disease 
symptoms or cure diseases altogether. There are two main strategies that can be employed to do this. 
The first is the use of synthetic miRNA mimics to restore the expression level of a particular miRNA 
back to normal levels [8]. This strategy presents many of the same challenges faced by siRNA 
therapies to be discussed later, such as stability and delivery. In addition, most miRNAs are pleiotropic 
hence altering levels of any given miRNA may result in unintended consequences. The second strategy 
is the use of miRNA “sponges” to block the action of over-expressed miRNAs [8]. Again, many of the 
same challenges apply to the use of sponges including design, delivery, and the pleiotropic nature of 
most miRNAs. 
2.3. Small Interfering RNAs 
2.3.1. Design 
The main focus of this review will be on the use of siRNA molecules as therapeutic agents. When 
considering the use of siRNA for therapeutic purposes, the first step is selection of an appropriately 
designed siRNA that takes into account potency, specificity and stability. Algorithms have been 
developed to assist in designing potent siRNA based on the target gene of interest, but once 
synthesized, these siRNAs must be experimentally evaluated to determine their efficacy in gene 
silencing. Specificity is another critical factor to consider. Although it has been demonstrated that 
siRNAs can have selective silencing of genes that differ by a single nucleotide in sequence [9], 
siRNAs can have “off-target” effects where expression of homologous mRNAs is altered or unrelated 
genes are altered [10]. Furthermore, siRNAs may induce the innate immune response by activating 
Toll-like receptors such as TLR7 that recognizes viral dsRNA. This could lead to a potentially harmful 
inflammatory response in patients. 
2.3.2. Stability 
When considering the use of siRNA molecules in in vivo models, stability of the molecule becomes 
another critical factor. Unprotected siRNA molecules are highly unstable and easily degraded in 
human plasma, with a half-life of only five minutes [11,12]. Chemical modifications are necessary to 
extend the half-life of siRNA in vivo without altering efficacy of gene silencing. Such chemical 
modifications include alterations in the phosphate groups linking nucleotides that confer exonuclease 
resistance or alterations (typically methylation) in the sugar residues that confer endonuclease 
resistance. The right balance between increased stability and maintained efficacy must be 
experimentally determined for siRNA molecules. 
2.3.3. Delivery 
Delivery of siRNA molecules to target cells/tissues is perhaps the most challenging factor of RNAi 
therapeutics. Due to its negative charge, siRNA molecules do not penetrate cell membranes easily. 
Only a few anatomically isolated sites have been shown to exhibit gene silencing after uptake of naked 
siRNA. This opens up the possibility for siRNA use in these areas (eyes, lungs, central nervous 
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system), but for more systemic use, delivery strategies must be developed. siRNA delivery can be 
achieved by a variety of strategies including lipid-based formulations [13], nanoparticles [14], and 
magnetofection [15]. However, these strategies are nonspecific, and cell-type specific delivery is still 
the most challenging step blocking the progress of RNAi therapy in modern medicine. In order to 
target siRNA to specific cell or tissue types, specificity must be built into the delivery agents or 
expressed shRNAs. Some strategies for cell-type specific delivery include antibody targeting [16], 
cell-penetrating peptides [17], chemical modifications[13], and aptamers [7], but each of these 
strategies presents certain drawbacks such as cytotoxicity or immunogenicity. 
Recently, Lima et al. demonstrated that single-stranded siRNA molecules are capable of 
functioning through the RNAi pathway in animals and result in potent gene silencing [18]. This 
finding is significant, because single-stranded siRNAs offer several advantages over dsRNAs. The lack 
of a second “passenger” strand reduces the risk for off-target effects, increasing specificity of the 
siRNA. More importantly, ssRNAs are easily delivered in vivo without any lipid-based transfection 
reagents or other delivery vectors. Chemically modified, naked single-stranded siRNAs can be 
delivered in vivo using a simple saline solution and result in potent gene silencing. This strategy may 
prove very useful for a systemic therapeutic approach using siRNA. However, in many diseases, 
specific cell-types or tissues must be targeted, thus a more specific delivery method must be developed. 
3. RNAi Therapeutics for Autoimmune Diseases 
The discovery of RNAi as a sequence-specific mechanism of gene regulation has made it an 
attractive concept for the development of new therapies. Numerous clinical trials for RNAi 
therapeutics have been completed or are ongoing for various diseases such as age-related macular 
degeneration (AMD), glaucoma, respiratory syncytial virus (RSV), asthma, liver cancer, and pancreatic 
cancer (clinical trials.gov). This review will focus on the progress of RNAi therapeutic development in 
autoimmune diseases. 
3.1. In Vitro Studies 
One study set out to develop a siRNA-based therapeutic targeting Sjögren’s syndrome (SjS), an 
autoimmune disease characterized by lymphocytic infiltration in the salivary and lacrimal glands 
resulting is severe dry mouth and dry eye symptoms due in part to apoptotic cell death of secretory 
acinar cells in the glands [19]. Currently, the only course of treatment available to SjS patients is 
immunosuppressive therapy and secretagogues, a class of drugs that stimulate secretion. Pauley et al. 
designed a conjugate composed of a siRNA molecule targeting caspase-3 and a muscarinic receptor 
agonist, carbachol [19]. Carbachol binds to muscarinic receptors inducing secretion and is endocytosed 
via receptor-mediated endocytosis. Linking a siRNA molecule to carbachol allows cellular uptake of 
the siRNA through this receptor-mediated endocytic pathway and specific delivery of the siRNA since 
only cells expressing muscarinic receptors including salivary acinar cells would be targeted. Pauley et al. 
showed that both the siRNA and carbachol remained functional after conjugation and HSG cells 
treated with conjugate (in the absence of transfection reagent) exhibited significant reduction in 
caspase-3 gene/protein expression, indicating that the conjugate is taken up by cells via muscarinic 
receptor-endocytosis. More importantly, inflammatory cytokine-induced apoptosis of HSG cells was 
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inhibited by conjugate treatment [19]. These data suggest that this strategy may be useful to prevent 
apoptotic cell death of secretory acinar cells in SjS patients, thus maintaining secretory function to 
improve quality of life for the patients. Further studies are needed to continue developing this 
conjugate for in vivo use. 
3.2. In Vivo Studies 
Several studies have examined the potential use of siRNA therapy in rheumatoid arthritis (RA).  
In 2005, Schiffelers et al. investigated the use of localized electroporation for in vivo delivery of 
siRNA into joint tissue of arthritic mice [20]. It was demonstrated that electroporation of anti-TNFα 
siRNA resulted in inhibition of joint inflammation in collagen-induced arthritis. A later study by 
Khoury et al. in 2006 utilized a DNA molecule for complexation and a cationic liposome for the 
intravenous delivery of anti-TNFα siRNA in collagen-induced arthritic mice [21]. When administered 
weekly, a 50%–70% reduction of TNF-α and an almost complete ablation of arthritic symptoms was 
observed in siRNA-treated mice. However, this systemic delivery approach resulted in uptake of 
siRNA by multiple organs including brain, lungs, liver and spleen. 
A more recent study extended this work by testing the efficacy of a “wraposome” to systemically 
deliver siRNA to arthritic joints in collagen-induced arthritic mice [22]. A wraposome consists of a 
core composed of a cationic lipid bilayer and siRNA complex enveloped in a neutrak lipid bilayer with 
polyethylene glycol on the surface. This design results in a neutral surface charge and prevents the 
non-specific binding of the liposome to plasma proteins after intravenous injection. Collagen-induced 
arthritic mice receiving siRNA targeting TNF-α via this systemic wraposome delivery exhibited 
significant decreases in the severity of arthritis coupled with reduction of TNF-α in the joints. 
Interestingly, the siRNA was mainly incorporated into macrophages and neutrophils in the inflamed 
synovium [22]. These findings support the potential therapeutic effects of suppressing inflammatory 
molecules via siRNA in rheumatoid arthritis. 
Yet another study examining the potential use of RNAi therapy in an arthritis animal model used a 
different strategy. Chen et al. used a lenti-viral vector to deliver short hairpin RNA targeting TLR7 in 
collagen-induced arthritic mice [23]. Again, severity of arthritis symptoms and expression of 
inflammatory mediators in the joints were reduced in treated mice compared to untreated mice.  
In addition to siRNA therapeutic potential in RA, certain miRNAs, particularly miR-146a, have 
been found to be differentially expressed in RA and other autoimmune diseases such as Sjögren's 
syndrome and systemic lupus erythematosus (SLE) [24–32]. One study demonstrated the potential 
therapeutic application of miR-146a for RA by demonstrating the inhibitory effect of miR-146a on 
osteoclastogenesis in vitro [33]. Furthermore, Nakasa et al. were able to demonstrate that intravenous 
administration of miR-146a resulted in the suppression of cartilage and bone destruction in a collagen-induced 
arthritis mouse model [33]. These findings support the therapeutic potential of miRNA modulation in 
autoimmune diseases. However, further studies are needed to identify and understand differentially 
expressed miRNAs in autoimmune disease patients. 
  
Pharmaceuticals 2013, 6 292 
 
 
4. Conclusions 
Despite significant progress in the field of RNAi therapeutics, there is still much research needed to 
perfect the design and delivery of siRNA in humans. Although several clinical trials using RNAi 
therapeutics have been completed, new problems have surfaced including unintended immunological 
effects, effects on the endogenous RNA silencing pathway, and the ultimate dilemma of how to 
effectively deliver siRNA in vivo. Regardless of these setbacks, hope still remains that with time, 
RNAi therapeutics will prove to be the next “superdrug” against a variety of human diseases. 
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